Clinical Resources for Clinicians · For clinicians
IV Iron in Pregnancy: Formulations, Timing and the Evidence
IV iron is the standard escalation for iron deficiency anemia in pregnancy when oral iron fails, can't be tolerated, or won't work fast enough. It's given in the second and third trimesters, not the first. Modern formulations replete iron in one to a few visits, raise hemoglobin faster than oral iron and rarely cause serious hypersensitivity reactions.
The clinical decision is usually the easy part. What usually goes wrong is timing: the decision gets made at 32 weeks, authorization takes two weeks, the first chair slot is a week after that, and the patient is infused at 36 weeks with hemoglobin that never had a chance to catch up. Most of this article is about avoiding that.
When IV iron is indicated
ACOG and BSH converge on a similar list:
- Oral iron failure: no meaningful hemoglobin rise after 2–4 weeks of adherent oral therapy
- Intolerance: GI side effects that prevent adequate dosing despite lower or alternate-day dosing
- Malabsorption: bariatric surgery, celiac disease, IBD or other conditions that impair duodenal absorption
- Late presentation: iron deficiency anemia found in the third trimester, without time for oral iron to restore hemoglobin before delivery
- Moderate to severe anemia where faster correction is clinically important
- Patients who decline blood products, who need hemoglobin optimized well ahead of delivery
BSH explicitly supports considering parenteral iron from the second trimester onward, and postpartum, for confirmed iron deficiency that hasn't responded to oral iron or can't be treated with it. Our piece on when oral iron fails walks through the stepwise approach.
Why not the first trimester
Animal and human data on first-trimester IV iron are limited, so guidelines and labeling recommend avoiding it without a compelling indication. Iron demand is also lowest in the first trimester, so oral iron has time to work. Practically: a patient found iron-deficient at an 8-week visit starts oral iron, and you set a reminder to recheck around 16–20 weeks so IV iron is ready to go early in the second trimester if she hasn't responded.
Formulations available in the US
All of these deliver elemental iron in a carbohydrate shell that limits free-iron release. They differ in maximum single dose, infusion time and side-effect profile. Use the current prescribing information for dosing.
| Formulation | Typical course | Practical notes |
|---|---|---|
| Iron sucrose | Multiple smaller doses over several visits | Longest experience in pregnancy; low reaction rate; most chair time and visits |
| Sodium ferric gluconate | Multiple smaller doses | Mostly used in dialysis; less common in obstetrics |
| Ferric carboxymaltose | One to two infusions | Large dose per visit; associated with hypophosphatemia, especially with repeat courses |
| Ferric derisomaltose | Often a single infusion | Large single dose; lower hypophosphatemia rates than ferric carboxymaltose in head-to-head trials |
| Ferumoxytol | Two doses separated by several days | Boxed warning for serious hypersensitivity; can interfere with MRI for months |
| Low-molecular-weight iron dextran | Total-dose infusion possible | Boxed warning for anaphylaxis; requires test dose; rarely first choice now |
High-molecular-weight iron dextran is no longer marketed in the US, and most anaphylaxis in older studies was linked to it. That history is still behind a lot of patient (and some colleague) anxiety about "iron infusions."
How to choose
No randomized evidence shows one formulation produces better maternal or neonatal outcomes. The choice comes down to:
- Visit burden. One- or two-visit products suit patients with transport, work or childcare barriers and late third-trimester presentations. For a patient commuting from the Rockaways or western Orange County, five iron sucrose visits is a real ask.
- Payer formulary. Many commercial and Medicaid managed care plans require trying a lower-cost product first. See our prior authorization guide.
- Phosphate. For patients likely to need repeat courses (ongoing GI loss, malabsorption), a product with less hypophosphatemia may be preferable.
- Local experience at the infusion center.
What the evidence shows
Randomized trials and meta-analyses comparing IV and oral iron in the second and third trimesters consistently show that IV iron:
- Raises hemoglobin faster, with the difference evident within 2–4 weeks
- Raises ferritin substantially more, rebuilding stores ahead of delivery and the postpartum period
- Causes fewer GI adverse effects
- Gets more patients to target hemoglobin by delivery
Evidence on harder outcomes (transfusion, PPH severity, neonatal outcomes, maternal depression) is less consistent, and most trials weren't powered for them. Several large trials from low- and middle-income countries reported improvements in maternal anemia at term, with mixed neonatal results. A fair counseling line: IV iron is a proven way to correct anemia and iron deficiency faster, not a proven way to change neonatal outcomes.
Safety
Hypersensitivity
Serious hypersensitivity reactions to modern IV iron are rare. Most infusion reactions are mild, self-limited reactions to labile iron (Fishbane reactions): flushing, chest tightness, back or joint pain, without hypotension, wheeze or stridor. They usually settle when the infusion is paused, and it can often restart at a slower rate.
Practice points, consistent with EMA recommendations:
- Give IV iron only where staff are trained and resuscitation equipment is available.
- Observe for at least 30 minutes after the infusion.
- Don't routinely premedicate with diphenhydramine. It can cause somnolence and hypotension that mimic a reaction.
- Asthma, atopy or a prior drug allergy raise risk modestly. Consider a slower rate rather than avoiding IV iron.
Our IV iron hypersensitivity article covers recognition and management.
Fetal considerations
Fetal bradycardia has been reported in association with maternal hypersensitivity reactions and hypotension, which is why maternal hemodynamic stability during the infusion matters. Many units monitor fetal heart rate before and after the infusion in viable pregnancies, per local protocol. If your patient is going to an outpatient infusion center rather than L&D, confirm what that center's protocol is.
Hypophosphatemia
Ferric carboxymaltose increases FGF23, driving renal phosphate wasting. Randomized comparisons in non-pregnant adults found much higher hypophosphatemia rates with ferric carboxymaltose than with ferric derisomaltose. After a single course it's usually transient and asymptomatic; with repeated courses it has been linked to osteomalacia. Check phosphate if a patient needs repeat dosing or reports new bone pain or profound fatigue.
Iron overload
Calculate the iron deficit (for example with the Ganzoni formula, using pre-pregnancy weight). Don't treat without confirmed iron deficiency, and don't give IV iron to patients with hemochromatosis or iron overload.
A practical protocol
- Confirm iron deficiency. ASH 2026 suggests a ferritin of 30 µg/L or lower in pregnancy (aligned with BSH), and notes that a threshold up to 50 may be appropriate in a pregnant patient who is anemic. With inflammation, consider ferritin below 100 µg/L or TSAT below 20%. Rule out hemoglobinopathy if microcytosis is out of proportion; in a diverse NYC panel, thalassemia trait is common enough to keep on the list.
- Document the indication: oral failure, intolerance, malabsorption or late presentation, with dates and hemoglobin values. Payers will ask.
- Choose the formulation based on visits, formulary and phosphate risk.
- Schedule early. Two- to four-week delays for authorization and chair time are common, and a third-trimester patient can't absorb them. Start the PA the day you decide.
- Recheck the CBC 2–4 weeks after the final dose, and ferritin no sooner than about 4 weeks, because ferritin reads falsely high right after an infusion.
- Plan for postpartum. Patients treated in pregnancy remain at high risk of postpartum anemia.
Referral partnership in New York
The most common failure point with IV iron in pregnancy isn't the decision to give it but the time it takes to get the patient into a chair. Premier Hematology & Oncology, which sponsors our professional resources, offers fast-track IV iron scheduling, referral pathways and co-management at infusion centers across New York City, Long Island and the Hudson Valley. See our hematology partners page for how to set it up.
Frequently asked questions
Is IV iron safe in pregnancy?
Modern IV iron formulations are widely used in the second and third trimesters, and serious reactions are rare. Guidelines generally avoid IV iron in the first trimester because safety data there are limited.
Which IV iron is best in pregnancy?
No formulation has been proven superior for maternal or neonatal outcomes. Single- or two-dose products such as ferric carboxymaltose, ferric derisomaltose and ferumoxytol need fewer visits; iron sucrose has the longest track record but needs multiple infusions.
How fast does hemoglobin rise after IV iron?
Reticulocytosis begins within days, and a meaningful hemoglobin rise is usually seen within 1–2 weeks. Trials generally show a faster and larger rise than with oral iron over the same period.
Does IV iron cause low phosphate?
Ferric carboxymaltose is associated with treatment-emergent hypophosphatemia more often than other formulations. It's usually asymptomatic after a single course, but it matters with repeated dosing.
Sources
- ASH — 2026 Guidelines for Diagnosis of Iron Deficiency (Blood Advances)
- ACOG — Anemia in Pregnancy (Practice Bulletin No. 233)
- British Society for Haematology — UK guidelines on the management of iron deficiency in pregnancy (2020)
- NATA — Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period (consensus statement)
- European Medicines Agency — New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines (2013)
- FDA — Prescribing information for iron sucrose, ferric carboxymaltose, ferumoxytol, ferric derisomaltose and iron dextran
This article is for general education and is not medical advice. It does not replace an evaluation by a licensed clinician who knows your history. If you think you have a medical emergency, call 911.